Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Cancer became recently the leading cause of death in industrialized countries. Even though standard treatments achieve significant effects in growth inhibition and tumor elimination, they cause severe side effects as most of the applied drugs exhibit only minor selectivity for the malignant tissue. Hence, specific addressing of tumor cells without affecting healthy tissue is currently a major desire in cancer therapy. Cell surface receptors, which bind peptides are frequently overexpressed on cancer cells and can therefore be considered as promising targets for selective tumor therapy. In this review, the benefits of peptides as tumor homing agents are presented and an overview of the most commonly addressed peptide receptors is given. A special focus was set on the bombesin receptor family and the neuropeptide Y receptor family. In the second part, the specific requirements of peptide-drug conjugates (PDC) and intelligent linker structures as an essential component of PDC are outlined. Furthermore, different drug cargos are presented including classical and recent toxic agents as well as radionuclides for diagnostic and therapeutic approaches. In the last part, boron neutron capture therapy as advanced targeted cancer therapy is introduced and past and recent developments are reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013 · cited 1×
“, 2015), altered epigenetic regulation mechanisms (Pfister and Ashworth, 2017), the overproduction of enzymes (DeBerardinis and Chandel, 2016) or changes in the cellular microenvironment such as a lower pH (Kato et al.”
BackgroundThe structure and function of G-protein-coupled receptors
Rosenbaum, D. M., Rasmussen, S. G. F., & Kobilka, B. K. (2009) · Nature · doi:10.1038/nature08144 · Cited by 2,534
Saito, G., Swanson, J. A., & Lee, K.-D. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00179-5 · Cited by 1,407
G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?
Sriram, K., & Insel, P. A. (2018) · Molecular Pharmacology · doi:10.1124/mol.117.111062 · Cited by 1,258
The Molecular Basis of G Protein–Coupled Receptor Activation
Weis, W. I., & Kobilka, B. K. (2018) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-033910 · Cited by 1,227 · cited 1×
“GPCR signaling is initiated by an extracellular ligand binding, which induces a conformational change in the receptor that initiates binding and activation of intracellular heterotrimeric G proteins (Gαi, Gαq, Gαs) (Weis and Kobilka, 2018).”
BackgroundTargeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799 · cited 1×
“For example, the dysregulation of translational regulators (Bhat et al., 2015), altered epigenetic regulation mechanisms (Pfister and Ashworth, 2017), the overproduction of enzymes (DeBerardinis and Chandel, 2016) or changes in the cellular microenvironment such as a lower pH (Kato et al.”
Background
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Peptides as a platform for targeted therapeutics for cancer: peptide–drug conjugates (PDCs)
Cooper, B. M., Iegre, J., O' Donovan, D. H., Ölwegård Halvarsson, M., & Spring, D. R. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00556h · Cited by 414
Bajracharya, R., Song, J. G., Patil, B. R., Lee, S. H., Noh, H.-M., Kim, D.-H., Kim, G.-L., Seo, S.-H., Park, J.-W., Jeong, S. H., et al. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2089296 · Cited by 246
“Additionally, antibodies can interact directly with host immune cells to initiate phagocytosis, antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, triggering cell death (Hoppenz et al., 2020).”
BackgroundSharma, S., Bhattacharya, S., Joshi, K., & Singh, S. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05331-8 · Cited by 13
Metadata
- Authors
- Hoppenz, P., Els-Heindl, S., & Beck-Sickinger, A. G.
- Venue
- Frontiers in Chemistry
- Publisher
- Frontiers Media SA
- Published
- 2020-07-07
- Volume
- 8
- Pages
- 571-571
- ISSN
- 2296-2646 (ISSN-L)
- OpenAlex
- W3041206783
- Cited by
- 242
- References
- 17
- FWCI
- 9.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.